Biologics License Application for Tisotumab Vedotin Submitted to the U.S. Food and Drug Administration
Genmab and Seagen have submitted a Biologics Licence Application or BLA to the U.S. Food and Drug Administration (FDA) for tisotumab vedotin.
The companies are...
MabPlex’s Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration
Leading Contract Development and Manufacturing Organization (CDMO) MabPlex International, serving the global biopharmaceutical and biotechnology industries with sites in China and the United States,...
First DLBCL Patient Dosed in Trial with Loncastuximab Tesirine
Swiss-base ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates (ADCs) targeting hematological malignancies and solid...
Indatuximab Ravtansine Shows Good Tolerability and Signs of Efficacy in Phase I/IIa Clinical Trial
Results for Phase I/IIa study confirms that indatuximab ravtansine, also known as BT-062, an antibody-drug conjugate being developed by Biotets, offers good tolerability and...
Novel Approach may Limit the Troubling Side Effects of Cancer Immunotherapy
Connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab | Yervoy®; Bristol-Myers Squibb Company) and anti-PD-L1 (atezolizumab | Tecentriq®; Genentech) to peptides that...
NICE Issues Technology Appraisal Guidance for Brentuximab Vedotin in CD30-Positive Hodgkin Lymphoma
Earlier this year, NICE, the United Kingdom's National Institute for Health and Care Excellence has issued a new Technology Appraisal Guidance for brentuximab vedotin (Adcetris®,...
Calicheamicin
Calicheamicin was discovered in the 1980s by a scientist from Lederle Laboratories (now Pfizer) while on vacation in Texas. The scientist collected a soil sample,...
Collagen-VI-Alpha-1 is a New Target and a Marker of Poor Outcome in Glioblastoma
Functional targeted therapy has unfortunately failed to improve the outcome of glioblastoma patients. While success stories evidenced by the use of antibody-drug conjugates or...
First Bispecific FynomAb® for Preclinical Development Nominated
Covagen, a privately owned Swiss company developing bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes-of-action...
CytomX’s Antibody Therapies Target Cancer, Leave Healthy Tissue Intact
Antibody technology holds promise for treating a wide array of diseases, and designing new antibodies is a hot area in biotech research right now....
